Kura Oncology's Q3 KOMZIFTI revenue rises 53% sequentially
KURA•Kura Oncology said third-quarter KOMZIFTI net product revenue rose 53% sequentially to $13.9 million. The company updated its 2026 collaboration revenue guidance to $40 million-$45 million and ended the quarter with $492.1 million in cash and short-term investments.
1. Product revenue growth
KOMZIFTI net product revenue rose 53% sequentially to $13.9 million, driven by a 30% increase in new patient starts and a 65% rise in total prescriptions. Kura Oncology said it maintained a majority share of new patient starts in its class.
2. Guidance and finances
Kura updated its 2026 collaboration revenue guidance to $40 million-$45 million and maintained its 2027 and 2028 guidance at $90 million-$110 million. The company reported a third-quarter net loss of $70.22 million and operating expenses of $97.50 million, and ended the quarter with $492.1 million in cash and short-term investments. It expects its financial resources to support operations beyond initial topline results from KOMET-017 in 2028.
